newsfilter
← Earnings
Earnings Releases·

Kymera Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $132.0 million for Q3 2026, an increase from $82.2 million in the prior year period, driven by R&D expenses rising to $128.5 million from $74.1 million; collaboration revenue fell to $0 from $2.8 million.
  • Maintains a cash, cash equivalents, and investment balance of $1.6 billion as of September 30, 2026, providing a runway into 2029, with no additional collaboration revenue expected for 2026.
  • Announced positive Phase 1 results for KT-579 (IRF5 Degrader) showing deep degradation and safety, while KT-621 (STAT6 Degrader) completed Phase 2b BROADEN2 enrollment in atopic dermatitis.
  • Outlined future clinical milestones including expected topline data for KT-621 BROADEN2 by year-end 2026, initiation of a Phase 3 atopic dermatitis trial by mid-2027, and a planned KT-579 Phase 1b trial in lupus by early 2027.
  • Executed key leadership appointments in July 2026, adding Terence Rooney, MD, as Chief Medical Officer and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development Program Leader.
Company
KYMERA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology